BBIO (BridgeBio Pharma) Accounts Payable : $27.5 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Accounts Payable?

BridgeBio Pharma's Accounts Payable for the quarter that ended in Mar. 2025 was $27.5 Mil.

BridgeBio Pharma's quarterly Accounts Payable declined from Sep. 2024 ($13.4 Mil) to Dec. 2024 ($9.6 Mil) but then increased from Dec. 2024 ($9.6 Mil) to Mar. 2025 ($27.5 Mil).

BridgeBio Pharma's annual Accounts Payable declined from Dec. 2022 ($11.6 Mil) to Dec. 2023 ($10.7 Mil) and declined from Dec. 2023 ($10.7 Mil) to Dec. 2024 ($9.6 Mil).

BridgeBio Pharma Accounts Payable Historical Data

The historical data trend for BridgeBio Pharma's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Accounts Payable Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable

Get a 7-Day Free Trial

8.95

11.88

11.56

10.66

9.62

BridgeBio Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable	Get a 7-Day Free Trial															4.73	18.13	13.36	9.62	27.53

BridgeBio Pharma Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

BridgeBio Pharma Accounts Payable Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (NAS:BBIO) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

1BBIO:Italy 2CL:Germany

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Executives

Neil Kumar	director, officer: See Remarks	C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Kkr Genetic Disorder L.p.	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Andrew Lo	director	C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Andrea Ellis	director	C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
Hannah Valantine	director	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Brian C Stephenson	officer: See Remarks	3160 PORTER DR, STE 250, PALO ALTO CA 94304
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Randal W Scott	director	171 MAIN STREET #225, LOS ALTOS CA 94022
Frank Mccormick	officer: Chairman of Oncology	C/O UCSF, 1450 3RD STREET, RM HD-371, SAN FRANCISCO CA 941439001
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Douglas A. Dachille	director	175 WATER STREET, NEW YORK NY 10038
Ronald J Daniels	director	C/O MOORE CORPORATION LIMITED, ONE CANTERBURY GREEN, STAMFORD CT 06901
Fred Hassan	director	C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
James C Momtazee	director	2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Brent L Saunders	director	2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033